Three-year risk of cervical precancer and cancer after the detection of low-risk human papillomavirus genotypes targeted by a commercial test

Obstetrics and Gynecology

Volumn 123, Issue 1, 2014, Pages 49-56

  Castle, Philip E ^a,b   Hunt, William C ^a,b   Langsfeld, Erika ^a,b   Wheeler, Cosette M ^a,b,c  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

ADULT; ARTICLE; CANCER INCIDENCE; CANCER RISK; CANCER SCREENING; CONTROLLED STUDY; DISEASE REGISTRY; DISEASE SEVERITY; FEMALE; GENOTYPE; HUMAN; HUMAN PAPILLOMAVIRUS 42; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 6; MAJOR CLINICAL STUDY; PAPANICOLAOU TEST; PAPILLOMA VIRUS; PAPILLOMAVIRUS INFECTION; PREDICTIVE VALUE; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; VACCINATION; VIRUS STRAIN; WART VIRUS;

ADULT; CERVICAL INTRAEPITHELIAL NEOPLASIA; FEMALE; HUMAN PAPILLOMAVIRUS 11; HUMANS; NEW MEXICO; PAPILLOMAVIRUS INFECTIONS; RISK ASSESSMENT; UTERINE CERVICAL DYSPLASIA; UTERINE CERVICAL NEOPLASMS;

EID: 84893640780     PISSN: 00297844     EISSN: 1873233X     Source Type: Journal    
DOI: 10.1097/AOG.0000000000000013     Document Type: Article

References (21)

1. Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam SL, Cain J, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin 2012;62:147-72.
2. Moyer VA. Screening for cervical cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2012;156:880-91.
3. Wright TC Jr, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D. 2006 consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocarcinoma in situ. J Low Genit Tract Dis 2007;11:223-39.
4. Wright TC Jr, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D. 2006 consensus guidelines for the management of women with abnormal cervical screening tests (published erratum appears in J Low Genit Tract Dis 2008;12:255). J Low Genit Tract Dis 2007;11:201-22.
5. Lee JW, Berkowitz Z, Saraiya M. Low-risk human papillomavirus testing and other nonrecommended human papillomavirus testing practices among U.S. health care providers. Obstet Gynecol 2011;118:4-13.
6. Saraiya M, Berkowitz Z, Yabroff KR, Wideroff L, Kobrin S, Benard V. Cervical cancer screening with both human papillomavirus and Papanicolaou testing vs Papanicolaou testing alone: what screening intervals are physicians recommending? Arch Intern Med 2010;170:977-85.
7. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet 2007;370:890-907.
8. Wheeler CM, Hunt WC, Cuzick J, Langsfeld E, Pearse A, Montoya GD, et al. A population-based study of human papillomavirus genotype prevalence in the United States: baseline measures prior to mass human papillomavirus vaccination. Int J Cancer 2012;132:198-207.
9. Peyton CL, Gravitt PE, Hunt WC, Hundley RS, Zhao M, Apple RJ, et al. Determinants of genital human papillomavirus detection in a US population. J Infect Dis 2001;183: 1554-64.
10. Gravitt PE, Peyton CL, Alessi TQ, Wheeler CM, Coutlee F, Hildesheim A, et al. Improved amplification of genital human papillomaviruses. J Clin Microbiol 2000;38:357-61.
11. Castle PE, Gravitt PE, Solomon D, Wheeler CM, Schiffman M. Comparison of linear array and line blot assay for detection of human papillomavirus and diagnosis of cervical precancer and cancer in the atypical squamous cell of undetermined significance and low-grade squamous intraepithelial lesion triage study. J Clin Microbiol 2008;46:109-17.
12. Solomon D, Davey D, Kurman R, Moriarty A, O'Connor D, Prey M, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 2002;287:2114-9.
13. Castle PE, Sideri M, Jeronimo J, Solomon D, Schiffman M. Risk assessment to guide the prevention of cervical cancer. J Low Genit Tract Dis 2008;12:1-7.
14. Castle PE, Stoler MH, Solomon D, Schiffman M. The relationship of community biopsy-diagnosed cervical intraepithelial neoplasia grade 2 to the quality control pathology-reviewed diagnoses: an ALTS report. Am J Clin Pathol 2007;127:805-15.
15. Trimble CL, Piantadosi S, Gravitt P, Ronnett B, Pizer E, Elko A, et al. Spontaneous regression of high-grade cervical dysplasia: effects of human papillomavirus type and HLA phenotype. Clin Cancer Res 2005;11:4717-23.
16. Castle PE, Schiffman M, Wheeler CM, Solomon D. Evidence for frequent regression of cervical intraepithelial neoplasiagrade 2. Obstet Gynecol 2009;113:18-25.
17. Belinson S, Smith JS, Myers E, Olshan A, Belinson J, Pretorius R, et al. Descriptive evidence that risk profiles for cervical intraepithelial neoplasia 1, 2, and 3 are unique. Cancer Epidemiol Biomarkers Prev 2008;17:2350-5.
18. Darragh TM, Colgan TJ, Cox JT, Heller DS, Henry MR, Luff RD, et al. The lower anogenital squamous terminology standardization project for HPV-associated lesions: background and consensus recommendations from the College of American Pathologists and the American Society for colposcopy and cervical pathology. Arch Pathol Lab Med 2012; 136:1266-97.
19. Dillner J, Rebolj M, Birembaut P, Petry KU, Szarewski A, Munk C, et al. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ 2008;337:a1754.
20. Wright TC Jr, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D; 2006 American Society for Colposcopy and Cervical Pathology-sponsored Consensus Conference. 2006 consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocarcinoma in situ. Am J Obstet Gynecol 2007;197:340-5.
21. Kyrgiou M, Koliopoulos G, Martin-Hirsch P, Arbyn M, Prendiville W, Paraskevaidis E. Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis. Lancet 2006;367: 489-98.